ID 774 - Fruktooligosacharydy z sacharozy

PL: Fruktooligosacharydy z sacharozy
EN: Fructoligosaccharides from sucrose
Pdf: fructooligosaccharides

Oświadczenie (2)

1. Charakterystyka żywności / składnika

The food constituent that is the subject of the health claim is fructooligosaccharides obtained from sucrose.
Fructooligosaccharides (FOS) obtained from sucrose are prepared by enzymatic elongation of sucrose, and consist of a mixture of kestose (glucose-fructose-fructose, GF2), nystose (GF3) and fructosylnystose (GF4), with an average degree of polymerisation (DPav) of 3.6, and are sometimes referred to as short-chain fructooligosaccharides. They differ from natural fructans by degree of polymerisation (DP) (only 10 % of native chicory inulins have a DP between 2 and 5) (Roberfroid, 2007), and from oligofructoses prepared by inulin hydrolysis (DP from 2 to 7, DPav 4) by the systematic presence of a glucose moiety.
The Panel considers that the food constituent, fructooligosaccharides (FOS) from sucrose, which is the subject of the health claims, is sufficiently characterised.

2.1. Zmniejszenie ilości potencjalnie patogennych mikroorganizmów przewodu pokarmowego (ID 774)

The claimed effect is “prebiotic/bifidogenic”. The Panel assumes that the target population is the general population.
In the context of the proposed wordings, the Panel assumes that the claimed effect refers to increasing numbers of bacteria which are considered to be “beneficial”.
The numbers/proportions of bacterial groups that would constitute a “beneficial” colon/gastro-intestinal flora have not been established. Increasing the number of any group of microorganisms, including lactobacilli and/or bifidobacteria, is not in itself considered to be a beneficial physiological effect.
The Panel considers that the evidence provided does not establish that increasing numbers of gastro-intestinal microorganisms is a beneficial physiological effect.
The Panel considers that the claimed effect, in the context of decreasing potentially pathogenic gastro-intestinal microorganisms, might be a beneficial physiological effect.
S) from sucrose related health claims
8 EFSA Journal 2010;9(4):2023

3.1. Zmniejszenie ilości potencjalnie patogennych mikroorganizmów przewodu pokarmowego (ID 774)

Among the references provided were reviews, textbooks and opinions/guidelines from authoritative bodies which either did not address the claimed effect or did not contain any original data which could be used for the scientific substantiation of the claimed effect. Some human studies were not related to the food constituent that is the subject of the claim, or examined the effect of FOS in combination with other substances, and several human and animal studies addressed outcomes unrelated to the claimed effect. The Panel considers that no conclusions can be drawn from these references for the scientific substantiation of the claimed effect. One conference report related to the effect of FOS on intestinal microbiota was not accessible to the Panel after having made every reasonable effort to retrieve it (Rochat et al., 1994).
Several human studies focused on the effects of FOS on faecal bifidobacteria (Bouhnik et al., 2004; Gibson and Wang, 1994a; Gibson and Wang, 1994b), or on bifidobacteria together with other bacterial groups (e.g. total aerobes, total anaerobes, staphylococci, enterococci, Bacteroides, enterobacteria, clostridia, fusobacteria, coliforms) (Bouhnik et al., 1996; Bouhnik et al., 1999; Bouhnik et al., 2006; Buddington et al., 1996; Gibson et al., 1995; Rao, 2001; Waligora-Dupriet et al., 2007). The Panel notes that the bacterial groups analysed in these studies are part of the commensal intestinal microbiota, and that the studies did not provide evidence for the characterisation of any of these groups as pathogens. In three human studies the effect of FOS on Clostridium perfringens was analysed (Mitsuoka et al., 1986; Mitsuoka et al., 1987; Tokunaga et al., 1993), but no information was given about the pathogenicity of the bacterial strains studied. The Panel considers that no conclusions can be drawn from these studies for the scientific substantiation of the claimed effect.
S) from sucrose related health claims
10 EFSA Journal 2010;9(4):2023
The Panel notes that no human studies have been provided from which conclusions can be drawn for the scientific substantiation of the claimed effect. The Panel considers that human studies are required for the substantiation of a claim, and that evidence provided in animal and in vitro studies is not sufficient to predict the occurrence of an effect of FOS consumption on decreasing potentially pathogenic intestinal microorganisms in humans.
The Panel concludes that a cause and effect relationship has not been established between the consumption of fructooligosaccharides from sucrose and decreasing potentially pathogenic intestinal microorganisms.

Warunki i możliwe ograniczenia stosowania oświadczenia

2.5g/ day